Bruno Buecher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7517784/publications.pdf

Version: 2024-02-01

34 papers	2,212 citations	516710 16 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	5357 citing authors

#	Article	IF	Citations
1	Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. European Journal of Medical Genetics, 2022, 65, 104385.	1.3	6
2	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. European Journal of Cancer, 2022, 162, 138-147.	2.8	4
3	Geneâ€•and pathwayâ€level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. International Journal of Cancer, 2021, 148, 1895-1909.	5.1	5
4	Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. Prostate, 2021, 81, 318-325.	2.3	7
5	Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. Breast Cancer Research, 2021, 23, 79.	5.0	3
6	Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. American Journal of Human Genetics, 2021, 108, 1907-1923.	6.2	14
7	Withholding the Introduction of Antiâ€Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wildâ€Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). Oncologist, 2020, 25, e266-e275.	3.7	3
8	MUTYH-associated polyposis: Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa). European Journal of Medical Genetics, 2020, 63, 104078.	1.3	13
9	National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract. European Journal of Medical Genetics, 2020, 63, 104080.	1.3	11
10	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. Genetics in Medicine, 2020, 22, 1533-1541.	2.4	17
11	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. Clinical Chemistry, 2020, 66, 606-613.	3.2	42
12	Prevalence of Pathogenic Variants of FAN1 in More Than 5000 Patients Assessed for Genetic Predisposition to Colorectal, Breast, Ovarian, or Other Cancers. Gastroenterology, 2019, 156, 1919-1920.	1.3	7
13	Interaction between IGF2â€PI3K axis and cancerâ€associatedâ€fibroblasts promotes anal squamous carcinogenesis. International Journal of Cancer, 2019, 145, 1852-1859.	5.1	13
14	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clinical Cancer Research, 2019, 25, 2109-2115.	7.0	65
15	Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144, 1962-1974.	5.1	50
16	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Research, 2018, 20, 28.	5.0	35
17	Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations. Familial Cancer, 2018, 17, 281-285.	1.9	5
18	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 1094-1106.	10.7	108

#	Article	IF	Citations
19	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5767-5771.	7.0	68
20	Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. European Journal of Human Genetics, 2017, 25, 1345-1353.	2.8	39
21	HPV circulating tumor DNA to monitor the efficacy of antiâ€PDâ€1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. International Journal of Cancer, 2017, 141, 1667-1670.	5.1	29
22	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. British Journal of Cancer, 2016, 114, 1387-1394.	6.4	43
23	GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16, 13.	2.6	13
24	Mutation screening of MIR146A/B and BRCA1/2 3â€²-UTRs in the GENESIS study. European Journal of Human Genetics, 2016, 24, 1324-1329.	2.8	8
25	Colorectal adenomatous polyposis syndromes: Genetic determinism, clinical presentation and recommendations for care. Bulletin Du Cancer, 2016, 103, 199-209.	1.6	8
26	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. European Journal of Human Genetics, 2016, 24, 99-105.	2.8	17
27	Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10, e0136192.	2.5	11
28	MUTYH Status and Colorectal Cancer Risk: Implication for Surveillance. Current Colorectal Cancer Reports, 2015, 11, 10-16.	0.5	0
29	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
30	Role of microsatellite instability in the management of colorectal cancers. Digestive and Liver Disease, 2013, 45, 441-449.	0.9	63
31	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
32	French experts report on MUTYH-associated polyposis (MAP). Familial Cancer, 2012, 11, 321-328.	1.9	23
33	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	5.0	78
34	Cancer Risks Associated With Germline Mutations in <emph type="ital">MLH1</emph>, <emph type="ital">MSH2</emph>, and <emph type="ital">MSH6</emph> Genes in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2011, 305, 2304.	7.4	878